IntraOp Medical Corporation today announced that Helios Berlin Buch became the fourth German hospital and the nineteenth European hospital to purchase a Mobetron for Intra-Operative Electron Radiation Therapy (IOERT).

Omeros Corporation today announced that the first patients have been treated in the Company's Phase 3 clinical program evaluating OMS302 in intra-ocular lens replacement surgery.

Intra-aortic balloon pump counterpulsation prior to PCI in patients with ST segment elevation MI does not reduce infarct size as measured by MRI, according to results from the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction (CRISP AMI) trial. Intra-aortic balloon counterpulsation is a procedure in which a balloon inserted in ...

Inserting intra-aortic balloon pumps prior to angioplasty in patients with acute myocardial infarction (AMI) does not reduce the scope of heart muscle damage, a condition referred to as infarct size, according to a new study conducted by Duke University Medical Center researchers.

According to a study report published online by Archives of Ophthalmology, one of the JAMA/Archives journals, eight eyes with retinoblastoma (a tumor of the retina of the eye) that were treated by intra-arterial chemotherapy (IAC), post-removal, showed evidence of ocular complications and variable response of the tumor to the treatment. ...

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.

ProTip SA, a medical device company dedicated to finding innovative solutions for patients suffering from larynx malfunctions, today announced that the company has achieved ISO 13485 Certification. ISO 13485 is an internationally recognized quality standard designed to ensure that medical device manufacturers have the necessary comprehensive quality management systems in ...

Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited (TSE: 4502, "Takeda"), announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia. This agreement is targeted worldwide, but ITI ...

NEW YORK, Oct. 1 /- Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor. Intra-Cellular Therapies presented preclinical data at the 2nd World Parkinson Congress held in Glasgow, Scotland, ...

New Intra-Nasal Cooling System May Improve Survival When Initiated Soon After... -- SAN DIEGO, California, August 16, 2010 /-

Techniques that keep brain arteries open (intracranial stenting) or inject clot-busting drugs directly to the brain (intra-arterial tPA) may be more effective than other urgent ischemic stroke treatments, researchers said at the American Stroke Association's International Stroke Conference 2010.

Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase I clinical study demonstrating ITI-007, the Company's lead antipsychotic drug, interacts with important targets in the living human brain. These key targets are critical to drug action in many neuropsychiatric and ...